Recruitment Open for Phase 2 Trial Aimed at Complete Eradication of Myeloma Cells
The University of Alabama at Birmingham (UAB) is recruiting patients with newly diagnosed multiple myeloma for a Phase 2 trial evaluating an…
Myeloma
FDA Names Cancer Vaccine Galinpepimut-S Orphan Drug as Possible Multiple Myeloma Treatment
The investigational cancer vaccine galinpepimut-S (GPS) has been designated an orphan drug by the U.S. Food and Drug Administration as a possible treatment of…
FDA Approves Darzalex Combo Therapy for Certain Newly Diagnosed Patients
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with standard therapy for the treatment of patients with newly-diagnosed multiple myeloma who…
Selinexor May Bring Hope to Heavily Treated Myeloma Patients, Trial Results Show
A quarter of heavily treated patients with penta-refractory multiple myeloma responded to Karyopharm‘s investigative oral therapy selinexor (KPT-330), according to top-line data from…
9/11 Firefighters at Greater Risk of Multiple Myeloma Precursor, Study Reports
New York City firefighters exposed to the 9/11 World Trade Center (WTC) disaster are at greater risk for developing a condition called monoclonal gammopathy of…
Stand Up to Cancer Awards $10 Million to ‘Dream Team’ Focused on Early Detection of Precursor Multiple Myeloma Conditions
Stand Up to Cancer (SU2C) recently awarded $10 million to a SU2C Dream Team that wants to move the treatment of multiple myeloma from…
Chip-based Blood Test Might Replace Bone Marrow Biopsies for Myeloma, Scientists Say
Researchers say they have developed a low-cost, reliable, chip-based blood test to detect multiple myeloma, which could replace the painful bone marrow biopsy. Their…
Phase 1 Trial for Investigational Therapy STRO-001 Treats First Myeloma, Lymphoma Patients
A Phase 1 clinical trial testing therapy candidate STRO-001 for lymphoma and myeloma has started treating its first patients, announced Sutro Biopharma, the therapy’s…
New Method of Classifying Malignant Myeloma Cells Improves Outcomes, Study Finds
A new method that selects and isolates malignant myeloma cells based on their size and molecular markers enables more precise detection of chromosomal abnormalities, University…
P-BCMA-101 Shows Early Effectiveness in First Multiple Myeloma Patients Treated in Phase 1 Trial
P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy, is safe and effective in relapsed or refractory multiple myeloma patients, results from the first three patients enrolled…
Recent Posts
- Germany clears pelareorep pancreatic cancer trial continuation
- FDA grants orphan drug status to novel brain cancer treatment
- Medicaid expansion can raise demand for gynecologic cancer care
- Under-the-skin Sarclisa found as effective as approved formulation
- FDA gives LYT-200 fast track status as potential AML treatment